| Literature DB >> 32724884 |
Kosuke Mima1, Nobutomo Miyanari1, Atsushi Morito1, Shinsei Yumoto1, Takashi Matsumoto1, Keisuke Kosumi1, Mitsuhiro Inoue1, Takao Mizumoto1, Tatsuo Kubota1, Hideo Baba2.
Abstract
AIM: With population aging, the number of frail patients with colorectal cancer has increased. The Clinical Frailty Scale (CFS) is a validated tool for assessing frailty, and higher scores indicate worse clinical outcomes following cardiovascular procedures. This retrospective study aimed to examine preoperative frailty in relation to recurrence and mortality following curative resection of colorectal cancer.Entities:
Keywords: elderly; geriatrics; gerontology; morbidity; neoplasm
Year: 2020 PMID: 32724884 PMCID: PMC7382441 DOI: 10.1002/ags3.12337
Source DB: PubMed Journal: Ann Gastroenterol Surg ISSN: 2475-0328
FIGURE 1Study flow diagram of patients with stage I, stage II, and stage III colon and rectal carcinoma who underwent curative resection at the National Hospital Organization Kumamoto Medical Center between January 2009 and December 2016
Clinical and pathological characteristics according to frailty
| Characteristic | All patients (n = 729) | Nonfrail (n = 476) | Frail (n = 253) |
|
|---|---|---|---|---|
| Gender | ||||
| Men | 385 (53%) | 266 (56%) | 119 (47%) | .023 |
| Women | 344 (47%) | 210 (44%) | 134 (53%) | |
| Age in years | ||||
| <75 | 397 (54%) | 307 (65%) | 90 (36%) | <.001 |
| ≥75 | 332 (46%) | 169 (35%) | 163 (64%) | |
| Body mass index (kg/m2) | ||||
| <25 | 580 (80%) | 362 (76%) | 218 (86%) | .001 |
| ≥25 | 149 (20%) | 114 (24%) | 35 (14%) | |
| ASA‐PS | ||||
| 1 or 2 | 574 (79%) | 413 (87%) | 161 (64%) | <.001 |
| 3 or 4 | 155 (21%) | 63 (13%) | 92 (36%) | |
| Obstruction or perforation | ||||
| Absent | 665 (91%) | 445 (93%) | 220 (87%) | .003 |
| Present | 64 (8.8%) | 31 (6.5%) | 33 (13%) | |
| Emergency operation | ||||
| Absent | 698 (96%) | 462 (97%) | 236 (93%) | .016 |
| Present | 31 (4.3%) | 14 (2.9%) | 17 (6.7%) | |
| Tumor location | ||||
| Proximal colon | 269 (37%) | 152 (32%) | 117 (46%) | <.001 |
| Distal colon | 310 (42%) | 214 (45%) | 96 (38%) | |
| Rectum | 150 (21%) | 110 (23%) | 40 (16%) | |
| CEA | ||||
| <5 ng/mL | 420 (58%) | 298 (63%) | 122 (48%) | <.001 |
| ≥5 ng/mL | 309 (42%) | 178 (37%) | 131 (52%) | |
| CA19‐9 | ||||
| <37 U/mL | 651 (89%) | 437 (92%) | 214 (85%) | .003 |
| ≥37 U/mL | 78 (11%) | 39 (8.2%) | 39 (15%) | |
| The Barthel index of ADLs | ||||
| 0‐59 | 160 (22%) | 14 (2.9%) | 146 (58%) | <.001 |
| 60‐84 | 62 (8.5%) | 11 (2.3%) | 51 (20%) | |
| 85‐100 | 507 (70%) | 451 (95%) | 56 (22%) | |
| Prognostic Nutritional Index | ||||
| Median (IQR) | 62 (50‐75) | 68 (57‐80) | 51 (40‐61) | <.001 |
| Disease stage | ||||
| I | 159 (22%) | 122 (26%) | 37 (15%) | .002 |
| II | 323 (44%) | 197 (41%) | 126 (50%) | |
| III | 247 (34%) | 157 (33%) | 90 (35%) | |
| Tumor differentiation | ||||
| Well | 683 (94%) | 451 (95%) | 232 (92%) | .11 |
| Poor or mucinous | 46 (6.3%) | 25 (5.3%) | 21 (8.3%) | |
Abbreviations: ASA, The American Society of Anesthesiologists; ASA‐PS, ASA physical status classification; CA19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen; IQR, interquartile range.
Categorical variables are presented as proportions. Non‐normally distributed variables are reported as medians with interquartile ranges.
Categorical data were compared using the chi‐square test or Fisher's exact test. Non‐normally distributed data were compared using the Mann‐Whitney U test.
FIGURE 2Kaplan–Meier curves for recurrence‐free survival (A) and overall survival (B) according to preoperative frailty. The P value was calculated by the log‐rank test (two‐sided)
Associations of frailty with recurrence‐free survival after curative resection in 725 patients with stage I–stage III colorectal cancer
| Univariable HR (95% CI) |
| Multivariable HR (95% CI) |
| |
|---|---|---|---|---|
|
| ||||
| Preoperative frailty | ||||
| Frail (vs nonfrail) | 2.33 (1.78‐3.05) | <.001 | 1.70 (1.25‐2.31) | <.001 |
| Age in years | ||||
| ≥75 (vs <75) | 1.77 (1.35‐2.33) | <.001 | 1.39 (1.02‐1.88) | .034 |
| ASA‐PS | ||||
| 3 or 4 (vs 1 or 2) | 1.51 (1.11‐2.04) | .010 | 0.93 (0.67‐1.29) | .67 |
| Obstruction or perforation | ||||
| Present (vs absent) | 1.73 (1.14‐2.53) | .012 | 1.49 (0.97‐2.23) | .07 |
| Tumor location | ||||
| Proximal colon (vs distal colon) | 1.46 (1.07‐1.99) | .016 | 1.23 (0.89‐1.70) | .21 |
| Rectum (vs distal colon) | 1.44 (1.00‐2.05) | .049 | 1.56 (1.05‐2.30) | .027 |
| CEA level | ||||
| ≥5 ng/mL (vs <5 ng/mL) | 1.55 (1.19‐2.04) | .001 | 0.97 (0.72‐1.31) | .85 |
| CA19‐9 level | ||||
| ≥37 U/mL (vs <37 U/mL) | 2.34 (1.62‐3.29) | <.001 | 1.86 (1.26‐2.68) | .002 |
| Intraoperative bleeding | ||||
| ≥200 mL (vs <200 mL) | 1.68 (1.28‐2.21) | <.001 | 1.36 (1.02‐1.80) | .039 |
| Anastomotic leakage | ||||
| Present (vs absent) | 1.79 (1.11‐2.75) | .019 | 1.77 (1.05‐2.85) | .032 |
| Disease stage | ||||
| II (vs I) | 1.41 (0.94‐2.18) | .10 | 1.27 (0.82‐2.01) | .28 |
| III (vs I) | 2.62 (1.78‐3.97) | <.001 | 2.85 (1.83‐4.53) | <.001 |
| Adjuvant chemotherapy | ||||
| Present (vs absent) | 0.57 (0.40‐0.79) | <.001 | 0.45 (0.30‐0.65) | <.001 |
Abbreviations: ASA, The American Society of Anesthesiologists; ASA‐PS, ASA physical status classification; CA19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio.
Multivariable Cox proportional hazards regression models included variables showing a univariable association (P < .05) with recurrence‐free survival.
Associations of frailty with overall survival after curative resection in 725 patients with stage I–stage III colorectal cancer
| Univariable HR (95% CI) |
| Multivariable HR (95% CI) |
| |
|---|---|---|---|---|
|
| ||||
| Preoperative frailty | ||||
| Frail (vs nonfrail) | 3.57 (2.54‐5.04) | <.001 | 2.04 (1.40‐2.99) | <.001 |
| Age in years | ||||
| ≥75 (vs <75) | 2.41 (1.71‐3.42) | <.001 | 1.60 (1.11‐2.33) | .011 |
| ASA‐PS | ||||
| 3 or 4 (vs 1 or 2) | 2.23 (1.55‐3.16) | <.001 | 1.21 (0.82‐1.76) | .33 |
| Emergency operation | ||||
| Present (vs absent) | 2.12 (1.12‐3.64) | .022 | 1.66 (0.88‐2.89) | .11 |
| CEA level | ||||
| ≥5 ng/mL (vs <5 ng/mL) | 1.65 (1.18‐2.32) | .004 | 1.12 (0.78‐1.63) | .54 |
| CA19‐9 level | ||||
| ≥37 U/mL (vs <37 U/mL) | 2.67 (1.72‐4.01) | <.001 | 1.95 (1.23‐3.00) | .005 |
| Intraoperative bleeding | ||||
| ≥200 mL (vs <200 mL) | 1.47 (1.04‐2.07) | .029 | 1.14 (0.80‐1.63) | 0.47 |
| Disease stage | ||||
| II (vs I) | 1.14 (0.69‐1.94) | .62 | 0.97 (0.56‐1.70) | 0.90 |
| III (vs I) | 2.34 (1.48‐3.85) | <.001 | 2.72 (1.61‐4.74) | <0.001 |
| Adjuvant chemotherapy | ||||
| Present (vs absent) | 0.26 (0.15‐0.43) | <.001 | 0.23 (0.12‐0.40) | <0.001 |
Abbreviations: ASA, The American Society of Anesthesiologists; ASA‐PS, ASA physical status classification; CA19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio.
Multivariable Cox proportional hazards regression models included variables showing a univariable association (P < .05) with overall survival.